Table 5.
Multivariate analysis of overall survival
| Effect | Hazard Ratio (95% CI) | p-value |
|---|---|---|
| Main Effect | 0.08 | |
| Hispanic | 1 | |
| Non-Hispanic Black | 0.99 (0.89–1.11) | 0.2 |
| Non-Hispanic White | 1.07 (0.97–1.18) | 0.9 |
| Age | <.0001 | |
| <45 | 1 | |
| 45–60 | 1.15 (1.02–1.30) | 0.02 |
| 61–75 | 1.33(1.18–1.50) | <.0001 |
| Gender | <.0001 | |
| Male | 1 | |
| Female | 0.87 (0.823–0.92) | |
| Karnofsky score | <.0001 | |
| ≥90% | 1 | |
| <90% | 1.23 (1.19–1.32) | |
| Missing | 1.14 (1.01–1.29) | |
| HCT-CI | <.0001 | |
| No comorbidity | 1 | |
| 1–2 | 1.04 (0.97–1.11) | 0.26 |
| ≥3 | 1.21 (1.13–1.29) | <.0001 |
| Missing | 0.87 (0.79–0.96) | 0.006 |
| Stage at diagnosis | <.0001 | |
| <III | 1 | |
| III | 1.46 (1.39–1.54) | <.0001 |
| Missing | 1.17 (1.02–1.34) | 0.02 |
| Time from diagnosis to transplant | <.0001 | |
| <6 months | 1 | |
| 6–12 months | 1.08 (1.01–1.15) | 0.03 |
| >12 months | 1.44 (1.34–1.54) | <.0001 |
| Missing | 2.13 (1.28–3.55) | 0.004 |
| Melphalan dose | <.0001 | |
| 140 mg/m2 | 1 | |
| 200 mg/m2 | 0.85 (0.80–0.91) | <.0001 |
| Missing | 0.41 (0.06–2.93) | 0.4 |
| Disease status at transplant | <.0001 | |
| sCR/CR | 1 | |
| VGPR | 1.22 (1.11–1.33) | <.0001 |
| PR | 1.32 (1.22–1.44) | <.0001 |
| SD/Relapse/Progression | 2.04 (1.84–2.25) | <.0001 |
| Missing | 1.39 (0.85–2.28) | 0.2 |
Abbreviations: CI, confidence interval; HCT-CI, hematopoietic cell transplantation-comorbidity index; CR, complete response; VGPR, very good partial response; PR, partial response; SD, stable disease